Clinical trials: System Lupus Erythematosus
Systemic Lupus Erythematosus
Phase 1 Study of Belimumab in Subjects With Systemic Lupus Erythematosus (SLE)
The purpose of thie study is to evaluate the safety, tolerability, immunogenicity, pharmacokinetics and pharmacodynamics of belimumab (LymphoStat-B™)in subjects with SLE.
- Trial name
- NCT00657007
- Testing
- belimumab
- Where
- 18 sites in United States
- Volunteers
- 70 people
- Sponsor
- Human Genome Sciences Inc.
SLE, Lupus Erythematosus, Systemic
Validation of a Mobile Phone Based on EPRO Tool in Subjects With Systemic Lupus Erythematosus
Systemic lupus erythematosus (SLE) may involve a variety of organ systems expressed differently from patient to patient, and so can be difficult to characterize clinically.
- Conditions
- SLE, Lupus Erythematosus, Systemic, Systemic Lupus Erythematosus
- Trial name
- VALUE (NCT03142711)
- Testing
- No Medical Intervention
- Where
- 10 sites in United States, Canada
- Volunteers
- 80 people
- Sponsor
- Lupus Research Alliance
Systemic Lupus Erythematosus
Anti-CD19 CAR-NK Cells in Refractory/Relapsed Systemic Lupus Erythematosus
This study is a single-center, open-label, single-arm trial. The aim of this study is to investigate the safety and efficacy of anti-CD19 CAR-NK cells in patients with refractory/relapsed systemic lupus erythematosus.
- Trial name
- NCT06421701
- Testing
- anti-CD19 CAR-NK cells
- Where
- China
- Volunteers
- 10 people
- Sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
Systemic Lupus Erythematosus (SLE)
Whole Health Empowerment for Endotypes of Lupus: Improving Quality of Life in SLE
For people living with people living with systemic lupus erythematosus (SLE) the symptoms with the largest impact on their quality of life - fatigue, pain, and brain fog - are not always addressed in rheumatology clinic visits.
- Trial name
- WHEEL (NCT06720584)
- Testing
- Health coach-led, online support program for people living with lupus
- Where
- United States
- Volunteers
- 36 people
- Sponsor
- Duke University
Systemic Lupus Erythematosus, Autoimmune Hemolytic Anemia
UCAR T-cell Therapy Targeting CD19/ BCMA in Patients With Relapse/ Refractory Autoimmune Diseases
This is an investigator-initiated trial to evaluate the safety and efficacy of universal allogeneic anti-CD19/BCMA CAR T-cells in With Relapse/Refractory Autoimmune Diseases.
- Conditions
- Systemic Lupus Erythematosus, Autoimmune Hemolytic Anemia, Myasthenia Gravis, Systemic Sclerosis
- Trial name
- NCT06978738
- Testing
- universal allogeneic anti-CD19/BCMA CAR T-cells
- Where
- China
- Volunteers
- 18 people
- Sponsor
- Changzhou No.2 People's Hospital
Lupus Erythematosus, Systemic, SLE
Improving the Assessment of SLE Disease Activity
Physicians' assessment of disease activity in SLE is fundamental but challenging. The Systemic Lupus Erythematosus Disease Activity Index (SLEDAI-2K) is one of the most commonly used disease activity indices.
- Trial name
- NCT03144063
- Where
- Canada
- Volunteers
- 247 people
- Sponsor
- University Health Network, Toronto
Systemic Lupus Erythematosus
Establishing the Salience of Type 1 Interferon Pathway Blockade in the Central Mechanisms of SLE Related Fatigue
Systemic Lupus Erythematosus (SLE) is a multi-system autoimmune disorder, characterised by activation of the interferon system. Of the multiple domains of this disease, patients identify fatigue as the most pervasive and…
- Trial name
- EPIC (NCT06784076)
- Testing
- Anifrolumab
- Volunteers
- 20 people
- Sponsor
- NHS Greater Glasgow and Clyde
Systemic Lupus Erythematosus
Study of CM355 in Patients With Systemic Lupus Erythematosus
This study was designed to investigate the safety and efficacy of CM355 in patients with refractory SLE.
- Trial name
- NCT07104344
- Testing
- CM355
- Where
- China
- Volunteers
- 5 people
- Sponsor
- Second Xiangya Hospital of Central South University
Lupus Erythematosus, Systemic
Physical Activity in Patients With Systemic Lupus Erythematosus
Background. Systemic lupus erythematosus is a chronic autoimmune disease. Among its main clinical manifestations are musculoskeletal symptoms such as myopathies, arthritis, arthralgias or osteonecrosis.
- Trial name
- NCT06919250
- Testing
- Patients with systemic lupus erythematosus
- Where
- Spain
- Volunteers
- 63 people
- Sponsor
- University of Oviedo
Systemic Lupus Erythematosus
Phase III Randomized, Double-Blind, Placebo-Controlled Study of Dehydroepiandrosterone in Women With Active Systemic Lupus Erythematosus
OBJECTIVES: I. Evaluate the safety and efficacy of synthetic dehydroepiandrosterone, GL701, in women with active systemic lupus erythematosus.
- Trial name
- NCT00004662
- Testing
- dehydroepiandrosterone
- Volunteers
- 300 people
- Sponsor
- National Center for Research Resources (NCRR)
Systemic Lupus Erythematosus
" TREX1 Gene Mutations and Their Role in Systemic Lupus Erythematosus
Systemic lupus erythematosus (SLE) is a multisystem autoimmune disease characterized by diverse clinical manifestations, prominently involving the skin.
- Trial name
- NCT07397728
- Testing
- TREX1 gene polymorphisms
- Where
- Egypt
- Volunteers
- 90 people, healthy volunteers welcome
- Sponsor
- South Valley University
Systemic Lupus Erythematosus Nephritis
Monitoring Lupus Nephritis Through Urinary Extracellular Vesicles
Lupus nephritis (LN) is a severe manifestation of systemic lupus erythematosus (SLE) that can lead to irreversible kidney damage if not detected and managed promptly.
- Trial name
- NCT06642402
- Testing
- Kidney biopsy, Urinary extracellular vesicle testing, Autoimmunity in plasma
- Where
- 4 sites in Denmark
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Kolding Sygehus
Lupus Erythematosus, Systemic
Achievement of LLDAS5 in Patients With Systemic Lupus Erythematosus Treated With Anifrolumab.
This is an observational, multicenter, prospective study on patients with systemic lupus erythematosus treated with anifrolumab in Italy aimed at evaluating the achievement of LLDAS5
- Trial name
- DAHLIA (NCT07330245)
- Testing
- Anifrolumab
- Where
- 22 sites in Italy
- Volunteers
- 218 people
- Sponsor
- AstraZeneca
Systemic Lupus Erythematosus (SLE)
An Exploratory Clinical Study of Anti-CD19 CAR NK Cells in the Treatment of Systemic Lupus Erythematosus
A single arm, open-label pilot study is designed to determine the safety and effectiveness of anti-cluster of differentiation antigen 19 (CD19) chimeric antigen receptor (CAR) natural killer (NK) cells (KN5501) in patients with…
- Trial name
- NCT06010472
- Testing
- anti-CD19 CAR NK cells (KN5501)
- Where
- China
- Volunteers
- 36 people
- Sponsor
- Changhai Hospital
Systemic Lupus Erythematosus
Single Dose Study to Investigate the Pharmacokinetics (PK) and Safety of Belimumab 200 Milligrams (mg) Intravenous and 200 mg Subcutaneous Via Auto-injector in Chinese Healthy Subjects
This is an open-label, randomized, parallel group, single dose study in healthy Chinese subjects. The purpose of this study is to characterize the pharmacokinetic profile and safety profile of 200 mg single dose of belimumab…
- Trial name
- NCT04136145
- Testing
- Belimumab for IV, Belimumab for SC
- Where
- China
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Systemic Lupus Erythematosus
Anifrolumab Pregnancy Study
This is a non-interventional multi-database post-authorisation study to assess pregnancy-related safety data from women with SLE exposed to Anifrolumab.
- Trial name
- ROSE (NCT07049653)
- Where
- United States
- Volunteers
- 500 people
- Sponsor
- AstraZeneca
Systemic Lupus Erythematosus
Study of Systemic Lupus Erythematosus
This protocol will evaluate patients with systemic lupus erythematosus (SLE) and their relatives to learn more about how the disease develops and changes over time.
- Trial name
- NCT00001372
- Where
- United States
- Volunteers
- 2,000 people, healthy volunteers welcome
- Sponsor
- National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
Systemic Lupus Erythematosus
Real World Evidence of Anifrolumab in Systemic Lupus Erythematosus: Investigator Initiated, Observational, Multicenter Study Evaluating Effectiveness and Safety of Anifrolumab in Active SLE Patients
BACKGROUND AND RATIONALE. The role of type I interferons (IFN) in innate and adaptive immunity has been extensively studied, establishing a key role for type I IFNs in immune homeostasis.
- Trial name
- REVEAL (NCT07215754)
- Where
- Italy
- Volunteers
- 300 people
- Sponsor
- University of Pisa
Systemic Lupus Erythematosus
The Diagnostic Utility of T Immunoglobulin G and T Immunoglobulin M Biomarkers in Patients With Systemic Lupus Erythematosus Disease : Associations With Disease Activity and Damage
The SLE is heterogeneous multisystem autoimmune disease with complex pathogenesis involves multiple cellular components of the innate and adaptive immune systems, presence of autoantibodies and immune complexes, engagement of the…
- Trial name
- NCT07136337
- Testing
- 4 ml. of fresh venous blood will be collected from each patient on EDTA tube and will be used for detection of the following : T cell immunoglobulin G ( TIgG) and T cell immunoglobulin M (TIgM) by
- Where
- Egypt
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- Assiut University
Lupus Erythematosus, Systemic
Subcutaneous Treatment In Randomized Subjects To Evaluate Safety And Efficacy In Generalized Lupus Erythematosus
The objective of this study is to evaluate and compare efficacy of 3 dose levels of PF-04236921 to placebo in subjects with generalized lupus using a measure called the Systemic Lupus Erythematosus (SLE) Responder Index.
- Trial name
- BUTTERFLY (NCT01405196)
- Testing
- PF-04236921
- Where
- 113 sites in United States, Argentina and 11 more
- Volunteers
- 183 people
- Sponsor
- Pfizer
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.